Efficacy of Botulinum Toxin Type A for Prevention of Post-Mastectomy Scar in Transmen: A Prospective, Randomized Study
6
item.page.dc.date.issued
2023-11-01
item.page.dc.type
item.page.dc.identifier.eissn
20726651
item.page.dc.identifier.doi
item.page.dc.identifier.scopus
2-s2.0-85177585979
item.page.oaire.citation.title
Toxins
item.page.oaire.citation.volume
15
item.page.oaire.citation.issue
11
item.page.dc.rights.holder
SCOPUS
item.page.dc.identifier.citation
Toxins Vol.15 No.11 (2023)
punsarn.item.page.citation
Winayanuwattikun W., Vachiramon V., Rattananukrom T., Palakornkitti P., Sitpahul N. Efficacy of Botulinum Toxin Type A for Prevention of Post-Mastectomy Scar in Transmen: A Prospective, Randomized Study. Toxins Vol.15 No.11 (2023). doi:10.3390/toxins15110636 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/91243
item.page.dc.title
Efficacy of Botulinum Toxin Type A for Prevention of Post-Mastectomy Scar in Transmen: A Prospective, Randomized Study
item.page.dc.contributor.author
item.page.oairecerif.author.affiliation
item.page.dc.contributor.other
item.page.dc.description.abstract
Background: Subcutaneous mastectomies in transmen have been gaining popularity. However, post-operative scars are an inevitable consequence. Recently, Botulinum neurotoxin A (BoNT-A) has shown positive effects in scar prevention. The objective of this study is to investigate the effectiveness of BoNT-A in scar prevention. Methods: Fifteen patients who had undergone subcutaneous mastectomy were included. At 14 days post-surgery, either incoBoNT-A or a placebo was injected into the scar on each side. The primary outcome assessment measured the scar’s severity using the Vancouver Scar Scale (VSS) and the Patient and Observer Scar Assessment Scale (POSAS). The secondary outcome assessment evaluated the scar’s color using a standard measurement device. Outcome assessments were conducted until 6 months post-surgery. Results: There were significantly lower VSS scores in the BoNT-A group compared to the placebo at the end of the study (7.43 ± 0.26 vs. 8.82 ± 0.26, p < 0.001). The objective assessment revealed a statistically significant decrease in redness values in the BoNT-A group compared to the placebo at 3 and 6 months. Conclusion: BoNT-A has demonstrated effectiveness in scar prevention by reducing the severity of postoperative scar formation and improving overall scar appearance.